CompletedPHASE1, PHASE2NCT03684811
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Studying Carcinoma of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Forma Therapeutics, Inc.
- Principal Investigator
- Emma Barrett, MD, MPHForma Therapeutics
- Intervention
- FT-2102(drug)
- Enrollment
- 93 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2022
Study locations (26)
- Banner MD Anderson, Gilbert, Arizona, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Northwestern University, Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Iowa, Holden Comprehensive Cancer Institute, Iowa City, Iowa, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Columbia University Medical Center, New York, New York, United States
- Baylor Scott and White Medical Center, Temple, Texas, United States
- University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States
- Medical College of Wisconsin, Froedtert Hospital, Milwaukee, Wisconsin, United States
- Austin Hospital, Heidelberg, Victoria, Australia
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03684811 on ClinicalTrials.govOther trials for Carcinoma of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07437859Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor MicroenvironmentPeking Union Medical College Hospital
- RECRUITINGPHASE1NCT07106827A Study of GV20-0251 in Advanced or Refractory Solid TumorsWest China Hospital
- RECRUITINGNCT07466602cfDNA Methylation for Liver Cancer Recurrence DetectionWuhan Ammunition Life-tech Co., Ltd
- RECRUITINGPHASE2NCT07105748HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)Fudan University
- RECRUITINGPHASE2NCT06766643Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver CancerTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNCT06849180Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal DataZhongda Hospital
- RECRUITINGNANCT06905015Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver ResectionWarangkana Lapisatepun
- RECRUITINGNCT06486454Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)HistoSonics, Inc.
See all trials for Carcinoma of liver and intrahepatic biliary tract →